REG - Sareum Holdings PLC - Sareum to Present at BioTrinity 2022 Conference

Sareum HoldingsAnnouncement

26/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220426:nRSZ2523Ja&default-theme=true

RNS Number : 2523J  Sareum Holdings PLC  26 April 2022

Sareum Holdings plc

("Sareum" or the "Company")

Sareum to Present at BioTrinity 2022 Conference

Cambridge, UK, 26 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist
drug development company, announces that its CEO, Dr Tim Mitchell, will give a
Company Showcase presentation at the BioTrinity 2022 conference, being held in
London on 26 and 27 April.

In his presentation, Dr Mitchell will provide updates on the progress of
Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801,
targeting autoimmune diseases and the severe inflammatory responses and
respiratory symptoms arising from Covid-19 and other viral infections; and
SDC-1802, targeting cancers.

A video copy of the presentation can be viewed by registered delegates
throughout the BioTrinity event and will also be available on Sareum's website
after the event: www.sareum.com (http://www.sareum.com) .

About BioTrinity

BioTrinity is an established, must-attend London conference that catalyses
growth and supports in-person re-engagement across the life sciences industry.

The event is attended by an audience of early stage and emerging life sciences
R&D companies, investors, big pharma, and other valued partners throughout
the life sciences ecosystem. The conference features a focused, relevant, and
stimulating programme, led by great speakers, who bring their knowledge,
expertise, and vision to the fore in exciting, high-quality sessions.

For more information on the BioTrinity event, please visit www.biotrinity.com
(http://www.biotrinity.com/) .

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                    01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                          020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel                                          020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                         020 3764 2341

 MEDiSTRAVA Consulting (Financial PR)

 Mark Swallow / George Underwood / Evelyn McCormack   020 3928 6900

About Sareum

Sareum is a specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and autoimmune
diseases. The Company aims to generate value through licensing its candidates
to international pharmaceutical and biotechnology companies at the preclinical
or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine
kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical
development as therapies for autoimmune diseases, including the 'cytokine
storm' immune system overreaction to Covid-19 and other viral infections,
(SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral,
selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell
replication and DNA damage repair mechanisms. Preliminary Phase 2 and
comprehensive preclinical data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in genetically
defined patients.

SRA737 was discovered and initially developed by scientists at The Institute
of Cancer Research in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to
Sierra Oncology Inc. Sierra continues to explore options that would enable the
development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

- Ends -

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBSGDSGBDDGDU